malaria drug – Misryoum reports WHO approval of a baby-specific malaria treatment, designed for dosing safety in very young infants.
A baby-specific malaria treatment has cleared a crucial global hurdle. with WHO approval marking a major step toward reaching the youngest patients who have historically been left without an age-appropriate option.. The decision centers on Coartem Baby. a formulation designed specifically for infants. bringing a long-needed focus to malaria care for the first months of life.
In many parts of Africa, malaria affects even very young children, including infants under six months.. Misryoum notes that until now. clinicians have largely relied on medicines formulated for older children. which can raise concerns about dosing mistakes and the likelihood of unwanted side effects in newborns and young infants.
That gap is precisely what Coartem Baby is intended to close.. The treatment can be used for infants as small as 2 kilograms and comes in sweet cherry-flavored tablets that dissolve into liquids. including breast milk.. Its active ingredients are artemether and lumefantrine, a combination widely used in malaria therapy.
WHO approval also includes prequalification, an indicator that a product meets international expectations for quality, safety, and effectiveness. For health systems, this matters because it can unlock easier public-sector procurement in countries where malaria remains a persistent challenge.
Meanwhile, the broader picture includes growing recognition that the “young babies can’t get malaria” idea is not accurate.. Research and clinical experience have increasingly shown that very young infants can still develop malaria. which has pushed developers and regulators to design treatments that match their physiology and practical dosing needs.
Misryoum believes this approval can reshape how early malaria cases are handled, because treatment availability is only half the battle.. The other half is ensuring that medicines are safe and usable in real-world hospital and community settings. where infants often require rapid decisions and careful dosing.
The pathway from development to rollout is already underway in at least one setting, with the drug introduced in Ghana. Misryoum reports that early use has been paired with clinician coordination to help manage access and monitor outcomes in real patients.
At the policy and funding level, the drug’s development has involved partnerships aimed at improving reach in malaria-endemic regions.. With international procurement and ongoing efforts in diagnostics. vaccines. and mosquito-control measures. the approved treatment adds another tool to a fight that has claimed hundreds of thousands of young lives.